Details for New Drug Application (NDA): 203441
✉ Email this page to a colleague
The generic ingredient in GATTEX KIT is teduglutide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the teduglutide profile page.
Summary for 203441
| Tradename: | GATTEX KIT |
| Applicant: | Takeda Pharms Usa |
| Ingredient: | teduglutide |
| Patents: | 2 |
Pharmacology for NDA: 203441
| Ingredient-type | Analogs/Derivatives Glucagon-Like Peptide 2 |
| Mechanism of Action | Glucagon-like Peptide-2 (GLP-2) Agonists |
Suppliers and Packaging for NDA: 203441
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GATTEX KIT | teduglutide | POWDER;SUBCUTANEOUS | 203441 | NDA | Takeda Pharmaceuticals America, Inc. | 68875-0101 | 68875-0101-2 | 30 VIAL in 1 CARTON (68875-0101-2) / .5 mL in 1 VIAL (68875-0101-1) |
| GATTEX KIT | teduglutide | POWDER;SUBCUTANEOUS | 203441 | NDA | Takeda Pharmaceuticals America, Inc. | 68875-0102 | 68875-0102-1 | 1 KIT in 1 CARTON (68875-0102-1) * .5 mL in 1 SYRINGE, PLASTIC * .7 mL in 1 PACKET * .5 mL in 1 VIAL (68875-0101-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;SUBCUTANEOUS | Strength | 5MG/VIAL | ||||
| Approval Date: | Dec 21, 2012 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | May 16, 2026 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT | ||||||||
| Patent: | 7,847,061*PED | Patent Expiration: | May 1, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | 9,060,992*PED | Patent Expiration: | May 1, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
